Can palbociclib/palbociclib be effective in treating patients with advanced breast cancer?

Palbociclib (Palbociclib) has shown remarkable results in the treatment of patients with advanced breast cancer. As an oral cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib can specifically act on breast cancer cells, inhibit their proliferation and spread, thereby effectively prolonging the survival of patients.

Palbociclib is mainly targeted at patients with advanced breast cancer who are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative. These patients often have poor response to traditional chemotherapy drugs and are prone to develop drug resistance. Palbociclib can inhibit the activity of CDK4/6 and block the growth cycle of tumor cells, thereby achieving the purpose of treatment.

Clinical studies have shown that the combination of palbociclib and aromatase inhibitors can significantly extend the progression-free survival (PFS) of patients with advanced breast cancer. In a randomized, double-blind, phase III clinical trial called PALOMA-2, palbociclib combined with letrozole was used as a first-line treatment for patients with ER+/HER2- advanced breast cancer. The median PFS reached 27.6 months, which was significantly better than the 14.5 months in the placebo plus letrozole group.

In addition, palbociclib also has good safety and tolerability. Although some adverse reactions may occur during use, such as leukopenia, fatigue, etc., these reactions are generally mild and can be alleviated by adjusting the drug dosage or symptomatic treatment.

Overall, palbociclib is an effective drug for the treatment of patients with advanced breast cancer and can bring significant survival benefits to patients. However, you still need to pay attention to possible adverse reactions during use and use the medication rationally under the guidance of a doctor.